University of Roma La Sapienza
uniroma1.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
394
Active
44
Phase 3
22
Total enrollment
102,108
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| PDD-TURBT with hexaminolevulinate | — | — | — | — | — | 1 | |
| CHX 0.12% | — | — | — | — | — | 1 | |
| Pentabiocel | — | — | — | — | — | 1 | |
| Somatostatin analog; chemotherapy | — | — | — | — | — | 1 | |
| Oral iron supplementation | — | — | — | — | — | 1 | |
| IV iron administration | — | — | — | — | — | 1 | |
| Magnesium-PEA-HMW Hyaluronic Acid-Vitamin B6-Vitamin D + Vaginal Progesterone | — | — | — | — | — | 1 | |
| Antiplatelet Agents | — | — | — | — | — | 1 |
Next readouts
- 2025-03
- 2025-07-31
- 2025-09-14
- 2025-12-31
- 2027-04-01
- 2028-07-01
- 2028-12
Top conditions
- Coronary Artery Disease25
- Obesity17
- Septic Shock8
- Bariatric Surgery Candidate6
- Wound Heal5
- Pain5
- Liver Cirrhosis4
- Fibromyalgia4
Frequently asked questions about University of Roma La Sapienza
- How many clinical trials does University of Roma La Sapienza have on ClinicalTrials.gov?
- University of Roma La Sapienza is listed as the lead sponsor on 394 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Roma La Sapienza's trials are in Phase 3?
- 22 of University of Roma La Sapienza's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does University of Roma La Sapienza focus on?
- University of Roma La Sapienza's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Obesity, Septic Shock, Bariatric Surgery Candidate, Wound Heal.
- When are University of Roma La Sapienza's next clinical trial readouts?
- University of Roma La Sapienza has 7 upcoming primary-completion readouts tracked here; the soonest is “Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara”, expected around 2025-03.